Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,742 GBX | +0.11% | -2.45% | +20.30% |
May. 28 | CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate | MT |
May. 27 | US, European nations consider vaccinating workers exposed to bird flu | RE |
Sales 2024 * | 31.63B 40.34B | Sales 2025 * | 33.58B 42.84B | Capitalization | 70.96B 90.51B |
---|---|---|---|---|---|
Net income 2024 * | 5.54B 7.07B | Net income 2025 * | 6.49B 8.28B | EV / Sales 2024 * | 2.63 x |
Net Debt 2024 * | 12.28B 15.66B | Net Debt 2025 * | 9.06B 11.56B | EV / Sales 2025 * | 2.38 x |
P/E ratio 2024 * |
12.7
x | P/E ratio 2025 * |
10.9
x | Employees | 70,212 |
Yield 2024 * |
3.51% | Yield 2025 * |
3.64% | Free-Float | 94.54% |
Latest transcript on GSK plc
1 day | -1.94% | ||
1 week | -0.91% | ||
Current month | +4.00% | ||
1 month | +5.26% | ||
3 months | +4.20% | ||
6 months | +23.25% | ||
Current year | +19.98% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 17 M€ | +7.15% | - | |
2.51% | 7 M€ | +9.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 1,744 | +0.20% | 720 613 |
24-05-28 | 1,740 | -1.94% | 4,684,441 |
24-05-24 | 1,774 | -0.20% | 4,163,301 |
24-05-23 | 1,778 | -0.59% | 6,820,675 |
24-05-22 | 1,789 | +1.85% | 10,458,110 |
Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.98% | 90.67B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.47% | 238B | |
+7.35% | 204B | |
-6.42% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- GSK Stock